A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
124 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Gsk Investigational Site
Garran, Australian Capital Territory, Australia
Desmond YipRecruiting - Gsk Investigational Site
Westmead, New South Wales, Australia
Ka Yeung Mark WongRecruiting - Gsk Investigational Site
Melbourne, Victoria, Australia
John ZalcbergRecruiting
- Gsk Investigational Site
Leuven, Belgium
Patrick SchoffskiRecruiting
- Gsk Investigational Site
Barretos, São Paulo, Brazil
Leticia CostaRecruiting - Gsk Investigational Site
São Caetano do Sul, São Paulo, Brazil
Daniel CuberoRecruiting - Gsk Investigational Site
Porto Alegre, Brazil
Andreas LutzRecruiting - Gsk Investigational Site
Recife, Brazil
Marcelo Ramos Tejo Ramos Tejo SalgadoRecruiting - Gsk Investigational Site
Vitória, Brazil
GLAUCIO BERTOLLORecruiting
- Gsk Investigational Site
Calgary, Alberta, Canada
Xiaolan FengRecruiting - Gsk Investigational Site
Toronto, Ontario, Canada
Albiruni Ryan Ryan Abdul Abdul RazakRecruiting - Gsk Investigational Site
Montreal, Quebec, Canada
Jonathan NoujaimRecruiting
- Gsk Investigational Site
Shanghai, Shanghai Municipality, China
Ye ZhouRecruiting - Gsk Investigational Site
Beijing, China
Jian LiRecruiting - Gsk Investigational Site
Hangzhou, China
Yu ZhengRecruiting - Gsk Investigational Site
Jinan, China
Lei CongRecruiting - Gsk Investigational Site
Shanghai, China
Ming WangRecruiting - Gsk Investigational Site
Wuhan, China
Kai-Xiong TaoRecruiting
- Gsk Investigational Site
Angers, France
pierre kubicekRecruiting - Gsk Investigational Site
Bordeaux, France
Antoine ItalianoRecruiting - Gsk Investigational Site
Lille, France
Loic LebellecRecruiting - Gsk Investigational Site
Lyon, France
Jean-Yves BlayRecruiting - Gsk Investigational Site
Marseille, France
Florence DuffaudRecruiting - Gsk Investigational Site
Saint-Herblain, France
Emmanuelle BompasRecruiting - Gsk Investigational Site
Toulouse, France
Thibaud ValentinRecruiting - Gsk Investigational Site
Villejuif, France
axel LE CESNERecruiting
- Gsk Investigational Site
Berlin, Germany
Peter ReichardtRecruiting - Gsk Investigational Site
Essen, Germany
Sebastian BauerRecruiting - Gsk Investigational Site
Mannheim, Germany
Bernd KasperRecruiting
- Gsk Investigational Site
Pécs, Hungary
László MangelRecruiting
- Gsk Investigational Site
Meldola, FC, Italy
Lorena GurrieriRecruiting - Gsk Investigational Site
Rozzano MI, Lombardy, Italy
Alexia BertuzziRecruiting - Gsk Investigational Site
Bari, Italy
Michele GuidaRecruiting - Gsk Investigational Site
Candiolo, Italy
Sandra AlibertiRecruiting - Gsk Investigational Site
Genova, Italy
Danila ComandiniRecruiting - Gsk Investigational Site
Milan, Italy
Elena Rosa FumagalliRecruiting - Gsk Investigational Site
Milan, Italy
Roberta Giovanna SanfilippoRecruiting - Gsk Investigational Site
Palermo, Italy
Giuseppe BadalamentiRecruiting - Gsk Investigational Site
Roma, Italy
Bruno VincenziRecruiting
- Gsk Investigational Site
Chiba, Japan
Saori MishimaRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Dec 2025
- Primary completion
- 30 May 2028
- Completion
- 29 Nov 2030
- Last update posted
- 12 Jun 2026
- Registered enrollment
- 450
- Registry id
- NCT07218926
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.